Adenomyosis Medical Services in China

Adenomyosis is a common, benign gynecological disorder characterized by the ectopic presence of endometrial glands and stroma within the myometrium—the muscular layer of the uterus. Unlike endometriosis, which involves endometrial-like tissue outside the uterus, adenomyosis represents an inward invasion, leading to uterine enlargement, diffuse or focal myometrial thickening, and often significant clinical symptoms. The exact pathogenesis remains incompletely understood but is thought to involve abnormal tissue repair following uterine trauma (e.g., childbirth, cesarean delivery, or uterine surgery), hormonal dysregulation—particularly estrogen-dependent proliferation—and possible stem cell migration from the basalis endometrium into the myometrium. Recent evidence also implicates chronic inflammation, immune dysfunction, and aberrant Wnt/β-catenin signaling in disease initiation and progression. Epidemiologically, adenomyosis affects an estimated 20–35% of reproductive-age women, though prevalence rises sharply with age—reaching up to 60–70% in women undergoing hysterectomy for symptomatic indications. It is frequently underdiagnosed due to overlapping symptoms with fibroids or endometriosis and limitations of conventional imaging; definitive diagnosis historically required histopathology post-hysterectomy, though high-resolution transvaginal ultrasound (TVUS) with expert sonographic criteria and MRI now enable non-invasive diagnosis with >90% sensitivity and specificity in specialized centers. Key risk factors include parity (especially vaginal delivery and cesarean section), prior uterine surgery (e.g., myomectomy, D&C), mid-to-late reproductive age (peak incidence 40–50 years), and possibly genetic predisposition. Notably, nulliparity does not exclude adenomyosis, and increasing numbers of cases are being identified in younger, childbearing women—including those with infertility or recurrent implantation failure. Clinically, adenomyosis profoundly impacts quality of life: heavy menstrual bleeding (menorrhagia) leads to iron-deficiency anemia, fatigue, and reduced work productivity; severe dysmenorrhea (often progressive and unresponsive to NSAIDs) disrupts daily functioning and sleep; chronic pelvic pain and deep dyspareunia strain intimate relationships; and infertility or recurrent pregnancy loss contributes to psychological distress, anxiety, and depression. Many patients report diminished sexual health, social withdrawal, and impaired emotional well-being—factors rarely captured in routine clinical assessments but critical to holistic management. Early recognition and individualized, multidisciplinary care—integrating reproductive endocrinology, minimally invasive surgery, pain medicine, and mental health support—are essential to mitigate long-term morbidity and preserve fertility when desired.

Adenomyosis is a benign gynecologic condition characterized by the ectopic presence of endometrial glands and stroma within the myometrium, resulting in uterine enlargement, chronic inflammation, smooth muscle hyperplasia, and aberrant tissue remodeling. The precise etiology remains incompletely elucidated, but current evidence supports a multifactorial pathogenesis involving abnormal tissue repair, hormonal dysregulation, and immunologic perturbations. A widely accepted mechanistic framework centers on 'invagination theory'—where trauma to the endometrial–myometrial junctional zone (JZ), often secondary to childbirth, cesarean delivery, or uterine surgery, disrupts the integrity of the basalis layer and facilitates downward migration of endometrial tissue into the myometrium. Concurrently, 'stem cell theory' proposes that bone marrow–derived or endometrial resident mesenchymal stem cells undergo aberrant differentiation and implantation within the myometrium under permissive hormonal and inflammatory conditions. Estrogen and progesterone play pivotal roles: adenomyotic lesions exhibit heightened local estrogen biosynthesis via upregulated aromatase (CYP19A1) and reduced 17β-hydroxysteroid dehydrogenase type 2 (HSD17B2), leading to intratissue estrogen excess and relative progesterone resistance—manifested by downregulation of progesterone receptor B (PR-B) and impaired decidualization. This hormonal milieu promotes glandular proliferation, fibroblast activation, and extracellular matrix deposition.

Triggers of symptom onset or clinical progression include parity—particularly vaginal delivery with cervical laceration or prolonged second stage labor—as well as uterine instrumentation (e.g., dilation and curettage, hysteroscopic resection, or repeated IUD insertions). Acute or chronic pelvic inflammatory disease may exacerbate local cytokine release (e.g., IL-6, TNF-α, TGF-β1), amplifying myometrial infiltration and fibrosis. Perimenopausal hormonal fluctuations can unmask previously subclinical disease due to erratic estrogen exposure and declining progesterone-mediated suppression.

Established risk factors encompass age (peak incidence 40–50 years), multiparity (≥3 deliveries), prior uterine surgery (especially cesarean section and myomectomy), and history of endometriosis or uterine leiomyomas—conditions sharing overlapping pathophysiologic pathways including JZ disruption and chronic inflammation. Nulliparity is not protective; emerging data suggest that infertility-related interventions (e.g., ovarian stimulation, embryo transfer) may modulate local immune tolerance and promote lesion establishment. Obesity (BMI ≥30 kg/m²) constitutes a significant modifiable risk factor, as adipose tissue contributes to systemic and intrauterine estrogen excess and secretes pro-inflammatory adipokines (leptin, resistin) that potentiate myometrial remodeling.

Genetic factors are increasingly recognized. Genome-wide association studies (GWAS) have identified susceptibility loci near genes involved in sex steroid metabolism (e.g., ESR1, CYP19A1), extracellular matrix organization (COL5A1, MMP2), and Wnt/β-catenin signaling (CTNNB1). Familial clustering is observed, with first-degree relatives of affected women demonstrating 2–3-fold increased prevalence. Polymorphisms in inflammatory response genes—including IL-1β, IL-6, and TNF-α promoters—are associated with earlier onset and greater lesion burden. Epigenetic dysregulation, particularly hypermethylation of HOXA10 and PR-B promoters, contributes to progesterone resistance and aberrant endometrial receptivity.

Environmental exposures also contribute. Long-term use of unopposed estrogen therapy (e.g., in menopausal hormone treatment without adequate progestogen) may accelerate lesion growth. Chronic psychosocial stress—via hypothalamic-pituitary-adrenal axis activation—elevates cortisol and catecholamines, which impair uterine natural killer (uNK) cell function and promote Th17/Treg imbalance, facilitating immune evasion of ectopic endometrial tissue. Endocrine-disrupting chemicals (EDCs), including bisphenol A (BPA), phthalates, and dioxins, act as xenoestrogens or anti-progestins, altering JZ integrity during critical windows (e.g., fetal development, puberty, reproductive aging). Occupational exposure to organochlorine pesticides has been correlated with increased adenomyosis prevalence in epidemiologic cohorts. Collectively, adenomyosis arises from dynamic interactions among genetic predisposition, hormonal milieu, immune dysfunction, mechanical injury, and environmental endocrine disruption—underscoring its classification as a complex, systems-level disorder of reproductive tract homeostasis.

Adenomyosis is a common, often underdiagnosed gynecologic disorder characterized by the ectopic presence of endometrial glands and stroma within the myometrium, resulting in progressive myometrial hypertrophy, inflammation, and fibrosis. It predominantly affects women of reproductive age—particularly those aged 35–50 years—and is frequently associated with parity, prior uterine surgery (e.g., cesarean delivery or dilation and curettage), and concurrent endometriosis or uterine leiomyomas. While asymptomatic cases are not uncommon—detected incidentally on imaging or histopathology—clinically significant adenomyosis manifests through a constellation of symptoms that significantly impair quality of life, fertility, and pelvic health.

Early symptoms are often subtle and nonspecific, leading to diagnostic delays averaging 3–5 years. Women may initially report mild, cyclical lower abdominal discomfort or a vague sensation of pelvic 'heaviness' worsening premenstrually. Intermittent, low-grade dysmenorrhea—distinct from typical menstrual cramps due to its progressive nature and resistance to conventional NSAIDs—is frequently the first recognizable sign. Menstrual flow may appear normal initially, though some patients notice subtle changes such as increased clotting or prolonged spotting in the luteal phase. Early-stage adenomyosis may also present with unexplained infertility or recurrent implantation failure in assisted reproductive technology (ART) cycles, even in the absence of overt pain or menorrhagia—reflecting underlying uterine contractility dysfunction, impaired decidualization, and altered endometrial receptivity.

Typical symptoms emerge as the disease advances and myometrial infiltration deepens. Severe, debilitating dysmenorrhea is nearly universal in symptomatic cases; it is typically midline, radiating to the lower back or thighs, and peaks on days 1–3 of menses. Menorrhagia—defined as menstrual blood loss exceeding 80 mL per cycle—is present in approximately 60–75% of patients and often coexists with polymenorrhea (shortened intermenstrual intervals) or metrorrhagia (intermenstrual bleeding). Uterine enlargement is common, with many patients describing a palpable 'bulky' or 'globular' uterus on self-examination or during clinical evaluation; on bimanual exam, the uterus is characteristically diffusely enlarged, globular, symmetrically tender, and nonmobile. Chronic pelvic pain—noncyclical, persistent, and often dull or aching—is reported by up to 40% of affected women and may be exacerbated by intercourse (deep dyspareunia), bowel movements (dyschezia), or bladder filling (dysuria).

Accompanying symptoms reflect secondary pathophysiologic consequences. Anemia—predominantly iron-deficiency anemia—develops in ~25% of women with prolonged menorrhagia, manifesting as fatigue, pallor, exertional dyspnea, and reduced exercise tolerance. Gastrointestinal symptoms—including bloating, constipation, and cyclic diarrhea—are frequent due to shared embryologic origin and neurovascular cross-talk between the uterus and bowel; these are more prevalent in diffuse adenomyosis involving the posterior myometrium. Urinary symptoms such as frequency, urgency, and nocturia may occur secondary to uterine compression of the bladder base or trigone, particularly in anterior wall-dominant disease. Psychological comorbidities—including anxiety, depression, and sexual dysfunction—are highly prevalent, correlating strongly with symptom severity, chronicity, and impact on daily functioning and intimate relationships.

Complications extend beyond symptomatic burden. Adenomyosis is a well-established cause of subfertility and recurrent pregnancy loss: it disrupts embryo implantation via aberrant HOX gene expression, impaired pinopode formation, abnormal uterine peristalsis, and localized pro-inflammatory cytokine milieu (elevated IL-6, TNF-α, and RANTES). Spontaneous miscarriage rates are elevated two- to threefold compared with controls. Obstetric complications include preterm birth, fetal growth restriction, placenta previa, and postpartum hemorrhage—attributable to defective decidualization, impaired trophoblast invasion, and compromised myometrial contractility. Rarely, severe adenomyosis may lead to uterine rupture during labor, especially in women with prior cesarean scars or extensive myometrial thinning. Long-standing, untreated disease can result in secondary adenomyoma formation, hydrosalpinx (via tubal compression), or obstructive uropathy.

Diagnosis relies on integration of clinical assessment, imaging, and histopathology. Transvaginal ultrasound (TVUS) is the first-line modality; hallmark features include myometrial cysts (>1 mm), asymmetric or diffuse myometrial thickening (>12 mm), fan-shaped striations radiating from the endometrium, and indistinct endomyometrial junctional zone (JZ) with JZ width >12 mm and irregular borders. Three-dimensional (3D) TVUS enhances detection of JZ distortion. MRI offers superior specificity and is indicated when ultrasound is inconclusive or surgical planning is required; characteristic findings include T2-weighted hypointense myometrial thickening with ill-defined margins, JZ widening (>12 mm), and 'venous lake' signal voids representing dilated vessels. Serum CA-125 may be modestly elevated (typically <200 U/mL) but lacks diagnostic specificity. Definitive diagnosis remains histopathologic—requiring demonstration of endometrial glands and stroma at least 2.5 mm beneath the endomyometrial junction in hysterectomy specimens—but biopsy is not clinically useful due to sampling error and invasiveness.

Differential diagnosis is critical to avoid misattribution. Leiomyomas (fibroids) may mimic adenomyosis clinically and sonographically but typically demonstrate discrete, hypoechoic masses with acoustic shadowing and preserved JZ architecture. Endometriosis—especially deep infiltrating endometriosis (DIE)—shares overlapping symptoms (dysmenorrhea, dyspareunia, infertility) but involves extrauterine implants and often presents with nodularity in the uterosacral ligaments or rectovaginal septum. Endometrial polyps or hyperplasia cause abnormal uterine bleeding but lack uterine enlargement or JZ disruption. Pelvic inflammatory disease (PID) may cause chronic pelvic pain and tenderness but is associated with fever, leukocytosis, and adnexal tenderness—not uterine bulk. Adenomyosis must also be distinguished from uterine sarcomas (e.g., leiomyosarcoma), which present with rapid uterine enlargement, postmenopausal bleeding, or necrotic imaging features. Finally, irritable bowel syndrome (IBS) and interstitial cystitis may replicate gastrointestinal or urinary symptoms but lack cyclical exacerbation and objective uterine findings.

Adenomyosis is a common gynecologic condition characterized by the ectopic presence of endometrial glands and stroma within the myometrium, resulting in uterine enlargement, chronic pelvic pain, menorrhagia, dysmenorrhea, and infertility. As a disorder frequently encountered in reproductive medicine departments, its management requires individualized, stage-adapted strategies that balance symptom control, fertility preservation, and long-term quality of life. Treatment selection depends on symptom severity, patient age, reproductive goals, lesion extent (diffuse vs. focal), and comorbidities such as endometriosis or leiomyomas.

Conservative treatment forms the cornerstone for patients desiring future fertility or those with mild-to-moderate symptoms. It emphasizes non-invasive, reversible interventions aimed at suppressing estrogen-driven glandular activity and reducing inflammation. Lifestyle modifications—including regular aerobic exercise, stress reduction techniques (e.g., mindfulness-based stress reduction), and dietary optimization (low-glycemic, anti-inflammatory diets rich in omega-3 fatty acids and antioxidants)—have demonstrated adjunctive benefits in mitigating pain and menstrual irregularity. Pelvic floor physical therapy is strongly recommended for patients with coexisting myofascial dysfunction or hypertonic pelvic floor muscles, which commonly exacerbate dyspareunia and chronic pelvic discomfort. Transcutaneous electrical nerve stimulation (TENS) and acupuncture—particularly when delivered by licensed practitioners with gynecologic specialization—may provide meaningful analgesia and improve menstrual cycle regulation through neuromodulatory and neuroendocrine pathways.

Pharmacologic management targets hormonal modulation and symptomatic relief. First-line agents include combined oral contraceptives (COCs), particularly low-dose monophasic formulations administered continuously (i.e., skipping placebo weeks) to suppress endometrial proliferation and reduce menstrual flow. Progestin-only therapies—such as levonorgestrel-releasing intrauterine systems (LNG-IUS; e.g., Mirena®, Kyleena®)—are highly effective for localized endometrial suppression, with >80% of patients reporting significant reductions in dysmenorrhea and menorrhagia after six months. For patients with contraindications to estrogen or suboptimal response to LNG-IUS, oral progestins (e.g., norethisterone 5 mg daily from day 5–26) or selective progesterone receptor modulators (SPRMs) like ulipristal acetate (though currently restricted in many jurisdictions due to hepatic safety concerns) may be considered under strict monitoring. Gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide acetate) induce temporary hypoestrogenism and are reserved for short-term (<6 months) preoperative use or acute symptom exacerbation; add-back therapy (e.g., norethindrone acetate + estradiol) is mandatory to mitigate bone mineral density loss and vasomotor symptoms. Emerging evidence supports the use of aromatase inhibitors (e.g., letrozole) in refractory cases, especially when local estrogen synthesis within adenomyotic tissue contributes to disease persistence.

Surgical intervention is indicated for severe, medically refractory symptoms, large-volume adenomyosis (>12 cm uterine size), or when fertility preservation is no longer desired. Hysterectomy remains the definitive cure but is contraindicated in women pursuing childbearing. Focal adenomyomectomy—performed via laparoscopy, robotic-assisted laparoscopy, or open abdominal approach—requires meticulous ultrasonographic or MRI-guided delineation of lesion margins and layered myometrial resection with tension-free closure. Success hinges on surgeon expertise: recurrence rates range from 15–35% at five years, and postoperative pregnancy rates average 40–60% among carefully selected candidates (age <38, preserved ovarian reserve, no coexisting tubal pathology). Uterine artery embolization (UAE) demonstrates moderate efficacy for pain reduction but carries higher risks of amenorrhea (10–20%) and diminished ovarian reserve, limiting its utility in reproductive-aged patients. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) offers a non-invasive alternative for select patients with well-defined, non-circumferential lesions; however, its impact on subsequent fertility remains incompletely characterized and should be pursued only within multidisciplinary fertility preservation programs.

China’s reproductive medicine centers offer distinct advantages in adenomyosis management. First, integration of traditional Chinese medicine (TCM) with evidence-based Western therapeutics is standardized and rigorously researched—clinical trials from institutions such as Peking University Third Hospital have validated synergistic effects of herbal formulas (e.g., Guizhi Fuling Wan derivatives) in reducing uterine volume and improving endometrial receptivity when combined with LNG-IUS. Second, China leads globally in minimally invasive surgical innovation: high-volume centers routinely perform robotic-assisted adenomyomectomy with real-time intraoperative ultrasound guidance and near-infrared fluorescence imaging to optimize margin assessment and perfusion mapping. Third, national registries (e.g., the China Adenomyosis Registry) enable robust longitudinal outcome tracking, informing personalized prognostication models incorporating MRI texture analysis, serum CA-125 kinetics, and AMH trajectories. Finally, streamlined access to advanced diagnostics—including 3T MRI with diffusion-weighted imaging and dynamic contrast-enhanced sequences—is widely available in tertiary reproductive centers, facilitating precise phenotyping (junctional zone thickness >12 mm, asymmetry, cystic changes) critical for treatment stratification.

Post-treatment recovery necessitates structured, multidisciplinary follow-up. Patients undergoing medical therapy should undergo clinical reassessment every 3 months for the first year, including pelvic examination, transvaginal ultrasound, and symptom scoring (e.g., Visual Analog Scale for pain, Pictorial Blood Loss Assessment Chart). Those who undergo surgery require serial MRI at 6 and 12 months to assess myometrial healing and detect early recurrence. All patients benefit from endometrial receptivity array (ERA) testing prior to embryo transfer if pursuing IVF, given adenomyosis-associated alterations in window-of-implantation timing. Nutritional counseling emphasizing iron repletion (for menorrhagia-related anemia), vitamin D optimization (linked to reduced inflammatory cytokines), and gut microbiome support (via prebiotics/probiotics) is integral. Psychological support—including cognitive behavioral therapy for pain-related catastrophizing—is routinely embedded in care pathways across leading Chinese reproductive centers. Long-term surveillance includes annual pelvic ultrasound and serum CA-125 monitoring, with prompt MRI referral for new-onset symptoms or progressive uterine enlargement. Ultimately, successful management of adenomyosis demands continuity across medical, surgical, and supportive domains—ensuring not only symptom resolution but also sustained reproductive autonomy and holistic well-being.